Statins alter neutrophil migration by modulating cellular Rho activity-a potential mechanism for statins-mediated pleotropic effects?

Journal of Leukocyte Biology

Volumn 85, Issue 1, 2009, Pages 186-193

  Maher, B M ^a   Ni Dhonnchu, T ^b   Burke, J P ^a   Soo, A ^a,b   Wood, A E ^b   Watson, R W G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Arthritis; Atherosclerosis; Crohn's disease; Ischemic reperfusion injury; Reductase

Indexed keywords

ATORVASTATIN; CELL ADHESION MOLECULE; CHEMOATTRACTANT; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; RHO FACTOR; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVITY; CELL ADHESION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE MIGRATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

CELLS, CULTURED; CHEMOTACTIC FACTORS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHIL INFILTRATION; NEUTROPHILS; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; PYRROLES; RHOA GTP-BINDING PROTEIN; SIMVASTATIN;

EID: 58149250276     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0608382     Document Type: Article

References (40)

1. Kougias, P., Chai, H., Lin, P. H., Yao, Q., Lumsdden, A. B., Chen, C. (2005) Defensins and cathelieidins: neutrophil peptide with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med. 9, 3-10.
2. Ueno, M., Moriyama, Y., Toda, R., Yotsumoto, G., Yamamoto, H., Fukumoto, Y., Sakasegawa, K., Nakamura, K., Sakata, R. (2001) Effect of a neutrophil elastase inhibitor (ONO-5046 Na) on ischemia/reperfusion injury using the left-sided heterotopic canine heart transplantation model. J. Heart Lung Transplant. 20, 889-896.
3. Jordan, J. E., Zhao, Z. Q., Vinten-Johansen. J. (1999) The role of neutrophils in myocardial ischemia-reperfusion injury, Cardiovasc. Res. 43, 860-878.
4. Hirayama, S., Shiraishi, T., Shirakusa, T., Higuchi, T., Miller, E. J. (2006) Prevention of neutrophil migration ameliorates rat lung allograft rejection. Mol. Med. 12, 208-213.
5. Akimoto, H., McDonald. T. O., Weyhrich, J. T., Thomas, R., Rothnie, C. L., Allen, M. D. (1996) Antibody to CD18 reduces neutrophil and T lymphocyte infiltration and vascular cell adhesion molecule-1 expression in cardiac rejection. Transplantation 61, 1610-1617.
6. Zehr, K. J., Herskowilz, A., Lee, P. C., Poston, R. S., Gillinov, A. M., Raurngartner. W. A. (1993) Neutrophil adhesion inhibition prolongs survival of cardiac allografts with hyperacute rejection. J. Heart Lung Transplant. 12, 837-844.
7. El-Sawy, T., Fairchild, R. (2005) Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 112, 320- 331.
8. Healy, D. G., Watson, R. W., O' Keane, C., Eagan. J. J., McCarthy, J. F., Hurley, J., Fitzpatrick. J., Wood, A. F. (2006) Neutrophil transendothelial migration potential predicts rejection severity in human cardiac transplantation. Eur. J. Cardiothorac. Surg. 29, 760-766.
9. Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro. D. R., Beere, P. A., Langendorfer. A., Stein, E. A., Kruyer, W., Gotto Jr., A. M. (1998) Primary prevention of acute coronary events with lovastatin in men and JAMA 279, 1615-1622.
10. Scandinavian Simvastatin Survival Study Group (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344, 1383-1389.
11. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the long-term intervention with pravastatin in ischemic disease (LIPID) study. N. Engl. J. Med. 339, 1349-1357.
12. Kobashigawa. J. A., Katznelson, S., Laks, H., Johnson. J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) Effect oi pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333, 621-627.
13. Wenke, K., Meiser, R., Thiery. J., Nagel, D., von Scheidt. W., Krobot. K., Steinbeck, G., Seidel, D., Reichart, B. (2003) Simvastatin initiated early after heart transplantation: 8 year prospective experience. Circulation 107, 93-97.
14. Johnson, B., Lacono, A., Zeevl, A., McCurry, K., Duncan, S. (2003) Statin usage is associated with improved function and survival of lung allografts. Am. J. Respir. Crit. Care Med. 167, 1271-1278.
15. Chello, M., Patti, G., Candura, D., Mastrobuoni, S., Di Sciasco, G., Agro. F., Carassiti. M., Covino, E. (2006) Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit. Care Med. 34, 660-667.
16. Chello, M., Anselmi, A., Spadaccio, C., Patti, G., Goffredo, C., Di Sciascio, G., Covino, F. (2007) Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Ann. Thorac. Surg. 83, 1374-1380.
17. Chello, M., Mastroroberto. P., Patti, G., D'Ambrosio, A., Cortez Morichetti, M., Di Sciascio, G., Covino, E. (2003) Simvastatin attenuates leukocyte-endothelial interactions after coronary revascularization with cardio pulmonary bypass. Heart 89, 538-543.
18. Guasti, L., Marino, F., Cosentino, M., Cimpanelli, M., Maio, R. C., Klersy, C., Crespi, C., Restelli, D., Simoni, C., Franzetti, I., Guadio, G., Marnini, P., Grandi, A. M., Lecchini, C., Venco, A. (2006) Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudal study. J. Hypertens. 24, 2423-2430.
19. Kaneider, N. C., Reinisch, C. M., Dunzendorfer, S., Meierhofer, C., Djanani, A., Wiedermann, C. J. (2001) Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis 158, 23-33.
20. Dunzendorfer, S., Rothbucher, D., Schratzberger, P., Reinisch, N., Kahler, C. M., Wiedermann, C. J. (1997) Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ. Res. 81, 963-969.
21. Hunninghake, D. B. (1992) HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 3, 22-28.
22. Stancu, C., Sima, A. (2001) Statins: Mechanisms of actions and effects. J. Cell. Mol. Med. 5, 378-387.
23. Takai, Y., Sasaki, T., Matozaki, T. (2001) Small GTP-binding proteins. Physiol. Rev. 81, 153-208.
24. Alblas, J., Ulfman, L., Hordijk, P., Koenderman, L. (2001) Activation of Rho A and ROCK are essential for detachment of migrating leukocytes. Mol. Biol. Cell 12, 2137-2145.
25. Mackarel, J. A., Russell, K. J., Brady, C. S., Fitzgerald, M. X., O'Connor, C. M. (2000) Interleukin-8 and leukotriene B4 but not formylmethionyl leucylphenylalanine stimulate CD18-independent migration of neutrophils across human pulmonary endothelial cells. Am. J. Respir. Cell Mol. Biol. 23, 154-161.
26. Madara, J. L., Colgan, S., Nusrat, A., Delp. C., Parkos, C. (1992) A simple approach to measurement of electrical parameters of cultured epithelial monolayers: use in assessing neutrophil-epithelial interactions, j. Tissue Cult. Methods 14, 209-216.
27. Liu, L., Schwartz, B. R., Lin, N., Winn, R. K., Harlan, J. M. (2002) Requirement for RhoA kinase activation in leukocyte de-adhesion. J. Immunol. 169, 2330-2336.
28. Cordle, A., Koeniqsknecht-Talboo, J., Wilkinson. B., Limpert, A., Landreth, G. (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280, 34202-34209.
29. Wassmann, S., Eaufs, U., Baumer, A. T., Muller, K., Ahlbory, K., Linz, W., Itter, G., Rosen, R., Bohm, M., Nickenig, G. (2001) HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemia hypertension via reduced production of reactive oxygen species. Hypertension 37, 1450-1457.
30. Liao, J. K. (2004) Statins: potent vascular anti-inflammatory agents. Int. j. Clin. Pract. Suppl. Oct, 41-48.
31. Matsuo, T., Iwade, K., Hirata, N., Yamashita, M., llegami, H., Tanaka, N., Aosaki, M., Kasanuki, H. (2005) Improvement of arterial stiffness by the anti-oxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholeslerolemia. Heart Vessels 20, 8-12.
32. Weber, C., Erl, W., Weber, K., Weber, P. (1997) HMG-CoA reductase inhibitors decrease GD11b expression and GD11b-dependenl adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 30, 1212-1217.
33. Okouchi, M., Okayama, N., Omi, H., Imaeda, K., Shimizu, M., Fukutomi, T., Itoh, M. (2003) Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen activated protein kinase activation. J. Diabetes Complications 17, 380-386.
34. Zhang, E. L., Casey, P. J. (1996) Protein prenylation; molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269.
35. Niggli, V. (1999) Rho kinase in human neutrophils; a role in signaling for myosin light chain kinase phosphorylation and cell migration. FEBS Lett. 445, 69-72.
36. Pozo, M., de Nicolas, R., Egido, J., Gonzalez-Cabrero, J. (2006) Simvastatin inhibits the migration and adhesion of monocytic cells and disorganizes the cytoskeleton of activated endothelial cells. Eur. J. Pharmacol. 548, 53-63
37. Ambruso, D. R., Knall, C., Abell, A. N., Panepinto, J., Kurkchuhasehe, A., Thurman, G., Gonzalez-Aller, C., Hiester, A., de Boer, M., Harbeck, R. J., Over, R., Johnson. G. L., Roos, D. (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc. Natl. Acad. Sci. USA 97, 4654-4659.
38. Williams, D. A., Tao, W., Yang, F., Kim, C., Gu, Y., Mansfield, P., Levine, J. E., Petryniak, B., Derrow, C. W., Harris, C., Jia, B., Zheng, Y., Ambruso, D. R., Lowe, J. B., Atkinson, S. J., Dinauer, M. C., Boxer, L. (2000) Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac 2, is associated with a human phagocytic immunodeficiency. Blood 96, 1646-1654.
39. Szczur, K., Xy, H., Atkinson, S., Zheng, Y., Filippi, M. D. (2006) Rho GTPase CDC42 regulates directionality and random movement via distinct MAPK pathways in neutrophils. Blood 108, 4205-4213.
40. Lin, S. J., Chen, Y. H., Lin, E. Y., Hsieh, S. Y., Wang. S. H., Lin, C. Y., Wang, Y. C., Ku, H. H., Chen, J. W., Chen, Y. L. (2007) Pravastatin induces thrombomodulin expression in TNF-α treated human aortic; endothelial cells by inhibiting Rac1 and CDC42 trans location and activity. J. Cell. Biochem. 101, 642-653.